Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

FDA OKs Agent to Differentiate Alzheimer’s

Dementia TodayPublished April 9, 20122 min read

Key points

  • The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.
  • The main value of the test, Skovronsky told MedPage Today during a telephone media briefing, will be in ruling out Alzheimer’s disease.
  • And many patients diagnosed with Alzheimer’s – as many as one in five – do not show amyloid plaques during autopsy, he noted.
  • The approval of the product is a “great advancement in nuclear medicine practice,” said Edward Coleman, MD, of Duke University Medical Center.

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD, the company’s brand development leader for the product.

The main value of the test, Skovronsky told MedPage Today during a telephone media briefing, will be in ruling out Alzheimer’s disease.

Although amyloid plaques are considered to be a hallmark of Alzheimer’s, he said, they also appear in other forms of dementia and in the course of normal aging.

And many patients diagnosed with Alzheimer’s – as many as one in five – do not show amyloid plaques during autopsy, he noted.

A florbetapir scan showing few or no amyloid plaques would rule out the disease, he said, adding “in those patients, physicians can then focus on looking for other causes of dementia.”

The approval of the product is a “great advancement in nuclear medicine practice,” said Edward Coleman, MD, of Duke University Medical Center.

“It may help give physicians additional information when evaluating patients with cognitive decline,” he told reporters during the media briefing

Coleman cautioned that the compound does add to a patient’s cumulative exposure to radiation.

He also added that, in response to FDA concerns about the reliability of the test, the results of the PET scan should only be interpreted by a physician who has gone through a “reader training program” that’s now available online.

The company said florbetapir was evaluated in three main clinical studies that examined healthy adult patients, patients with a range of cognitive disorders, and some terminally ill patients who had agreed to have their brains evaluated post mortem.

In one study, the company said in a release, post-mortem cortical amyloid burden was highly correlated with median scores on the florbetapir scans, with a correlation coefficient of r=0.78 and a significance level of P

<0.0001.

Florbetapir scans had a median sensitivity of 92% and specificity of 95% for readers who had in-person training and 82% and 95%, respectively, for readers trained online.

The most common patient adverse effect in the clinical trials was headache, reported by 1.8% of participants, followed by musculoskeletal pain, fatigue, and nausea.

###

By

Michael Smith, North American Correspondent, MedPage Today

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.